中国医院用药评价与分析2019，Vol.19Issue(2)：143-146,4.DOI:10.14009/j.issn.1672-2124.2019.02.005
右美托咪定用于重症颅脑损伤患者的效果观察
Observation on Efficacy of Dexmedetomidine in Treatment of Severe Craniocerebral Injury
摘要
Abstract
OBJECTIVE: To evaluate the effects of dexmedetomidine in treatment of patients with severe craniocerebral injury, so as to provide references for the selection of sedation therapy. METHODS: 160 patients with moderate/severe craniocerebral injury admitted into ICU in the First Hospital of Shijiazhuang from Apr. 2017 to Apr. 2018 were selected and divided into control group and observation group according to the admission sequences, with 80 cases in each group. The control group was treated with midazolam for sedation and analgesia, while the observation group was given dexmedetomidine. Differences in heart rates (HR), respiratory rates (RR), mean arterial pressure (MAP), partial pressure of arterial oxygen (PaO2), partial pressure of arterial carbon dioxide (PaCO2), dosage of mannitol, wake-up time after stopping the infusion of sedatives (the time when the Richmond sedation score was restored to 0 point) and Glasgow coma scale (GCS) before and after wake-up at 24 h, 48 h and 72 h after ICU admission between two groups were compared; during follow-up for 3-6 months, the recovery rates of two groups were compared. RESULTS: At 24 h, 48 h and 72 h after ICU admission, the HR, RR, MAP, PaO2 and PaCO2 of both groups had been significantly improved than those of right after admission, and those of observation group were significantly better than the control group, with statistically significant differences (P＜0.05); the dosages of mannitol of observation group at 24 h, 48 h and 72 h after ICU admission were significantly lower than those of the control group, with statistically significant differences (P＜0.05); the wake-up time of observation group was significantly shorter than that of the control group, with significantly lower difference value of GCS between before and after wake-up, with statistically significant differences (P＜0.05); during follow-up for 3-6 months, the recovery rate of observation group was significantly higher than that of the control group, with statistically significant difference (P＜0.05). CONCLUSIONS: The sedative effect of dexmedetomidine for sedation and analgesia in patients with severe craniocerebral injury is significantly better than that of midazolam, which can effectively improve short-term prognosis and safety.关键词
重症颅脑损伤/右美托咪定/镇静躁动评分/临床研究Key words
Severe craniocerebral injury/Dexmedetomidine/Sedation-agitation scale/Clinical research分类
医药卫生引用本文复制引用
宋贺,张金峰,杨磊,唐蕊,左书浩,苏现辉,门焕丽..右美托咪定用于重症颅脑损伤患者的效果观察[J].中国医院用药评价与分析,2019,19(2):143-146,4.基金项目
河北省重点研发计划自筹项目-健康医疗与生物医药专项(No.172777195) （No.172777195）
